Addus HomeCare (NASDAQ:ADUS) Stock Rating Reaffirmed by Macquarie

Addus HomeCare (NASDAQ:ADUS)‘s stock had its “outperform” rating restated by investment analysts at Macquarie in a report issued on Friday, Benzinga reports. They presently have a $139.00 target price on the stock. Macquarie’s target price suggests a potential upside of 6.41% from the company’s previous close.

ADUS has been the topic of a number of other reports. Oppenheimer upped their price target on shares of Addus HomeCare from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 23rd. StockNews.com lowered Addus HomeCare from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 7th. TD Cowen lifted their price target on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Stephens reissued an “overweight” rating and issued a $138.00 price target on shares of Addus HomeCare in a research note on Tuesday, August 6th. Finally, KeyCorp began coverage on shares of Addus HomeCare in a research report on Friday. They set an “overweight” rating and a $150.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $131.38.

Addus HomeCare Trading Up 2.5 %

Shares of NASDAQ ADUS opened at $130.63 on Friday. The firm has a market capitalization of $2.36 billion, a PE ratio of 32.41, a PEG ratio of 2.33 and a beta of 1.04. Addus HomeCare has a one year low of $78.35 and a one year high of $136.12. The business has a 50-day moving average price of $129.54 and a two-hundred day moving average price of $117.24.

Addus HomeCare (NASDAQ:ADUS) last posted its quarterly earnings results on Monday, August 5th. The company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.21 by $0.14. The business had revenue of $286.90 million during the quarter, compared to analysts’ expectations of $284.90 million. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company posted $0.94 earnings per share. Research analysts anticipate that Addus HomeCare will post 4.58 EPS for the current year.

Insider Buying and Selling at Addus HomeCare

In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the sale, the executive vice president now directly owns 7,215 shares in the company, valued at approximately $961,687.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Michael D. Wattenbarger sold 21,917 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the transaction, the executive vice president now owns 7,215 shares of the company’s stock, valued at approximately $961,687.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Esteban Lopez sold 500 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $127.50, for a total value of $63,750.00. Following the sale, the director now owns 3,366 shares of the company’s stock, valued at approximately $429,165. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 22,917 shares of company stock worth $3,050,082 over the last 90 days. Insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Addus HomeCare

Several hedge funds and other institutional investors have recently modified their holdings of ADUS. Creative Planning raised its stake in Addus HomeCare by 5.8% during the 3rd quarter. Creative Planning now owns 4,910 shares of the company’s stock valued at $653,000 after purchasing an additional 267 shares during the last quarter. Oliver Luxxe Assets LLC raised its position in shares of Addus HomeCare by 244.8% during the third quarter. Oliver Luxxe Assets LLC now owns 16,512 shares of the company’s stock valued at $2,197,000 after buying an additional 11,723 shares during the last quarter. Redhawk Wealth Advisors Inc. acquired a new position in shares of Addus HomeCare during the third quarter valued at about $922,000. Inspire Investing LLC lifted its stake in shares of Addus HomeCare by 3.3% in the third quarter. Inspire Investing LLC now owns 3,111 shares of the company’s stock valued at $414,000 after buying an additional 100 shares during the period. Finally, GAMMA Investing LLC grew its position in Addus HomeCare by 25.7% during the third quarter. GAMMA Investing LLC now owns 935 shares of the company’s stock worth $124,000 after buying an additional 191 shares in the last quarter. Institutional investors and hedge funds own 95.35% of the company’s stock.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.